BioRestorative Therapies shareholders approve reverse stock split, reject Nevada reincorporation

BioRestorative Therapies, Inc.

Elected Nickolay Kukekov as Class I director: 1.49B for, 132.6M withheld, 452M broker non-votes.
Approved 2021 Stock Incentive Plan: 1.33B for, 210M against, 80.8M abstentions.
Rejected reincorporation from Delaware to Nevada: 1.48B for but 4.4M abstentions, needed majority; broker non-votes 452M.
Authorized Board to effect reverse stock split at ratio 1:20 to 1:4000 with discretion; 1.65B for, 396M against.
Ratified Friedman LLP as auditor for FY2021: 1.93B for, 90.2M against, 50M abstentions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.